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Nematode parasitosis causes significant mortality and morbidity in humans and
considerable losses in livestock and domestic animals. The acquisition of resistance
to current anthelmintic drugs has prompted the search for new compounds for which
the free-living nematode Caenorhabditis elegans has emerged as a valuable platform.
We have previously synthetized a small library of oxygenated tricyclic compounds
and determined that dibenzo[b,e]oxepin-11(6H)-one (doxepinone) inhibits C. elegans
motility. Because doxepinone shows potential anthelmintic activity, we explored its
behavioral effects and deciphered its target site and mechanism of action on C. elegans.
Doxepinone reduces swimming rate, induces paralysis, and decreases the rate of
pharyngeal pumping required for feeding, indicating a marked anthelmintic activity. To
identify the main drug targets, we performed an in vivo screening of selected strains
carrying mutations in Cys-loop receptors involved in worm locomotion for determining
resistance to doxepinone effects. A mutant strain that lacks subunit genes of the
invertebrate glutamate-gated chloride channels (GluCl), which are targets of the widely
used antiparasitic ivermectin (IVM), is resistant to doxepinone effects. To unravel the
molecular mechanism, we measured whole-cell currents from GluClα1/β receptors
expressed in mammalian cells. Glutamate elicits macroscopic currents whereas no
responses are elicited by doxepinone, indicating that it is not an agonist of GluCls.
Preincubation of the cell with doxepinone produces a statistically significant decrease of
the decay time constant and net charge of glutamate-elicited currents, indicating that it
inhibits GluCls, which contrasts to IVM molecular actions. Thus, we identify doxepinone
as an attractive scaffold with promising anthelmintic activity and propose the inhibition
of GluCls as a potential anthelmintic mechanism of action.
Keywords: C. elegans, Cys-loop receptors, glutamate-activated chloride channels, patch-clamp, anthelmintic
Abbreviations: ECS, extracellular solution; GluCl, glutamate-gated chloride channel; ICS, intracellular solution; IVM,
ivermectin; L-AChR, levamisole-sensitive acetylcholine receptor; N-AChR, nicotine-sensitive acetylcholine receptor; nAChR,
nicotinic acetylcholine receptor; NGM, nematode growth medium; τd , current decay time constant.
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INTRODUCTION
Nematode parasitosis is an important cause of mortality
and morbidity in humans and affects livestock and domestic
animals. As many as one-third of the world’s population
harbors infections with helminths. Also, nematodes have
an important negative impact on animal productivity
worldwide. The reduced anthelmintic drug development
and the ever-increasing resistance of nematodes to the limited
number of drugs have become a global concern for veterinary
and human health.
Parasitic nematodes are not ideal laboratory animals for
drug screening due to the difficulty for genetic manipulation
and the need for infected host animals. C. elegans shares
physiological and pharmacological features with parasitic
nematodes and it is sensitive to most anthelmintic drugs. The
major neurotransmitter receptors are similar between C. elegans
and parasitic species (Angstadt et al., 1989; Holden-Dye and
Walker, 2007). Thus, the free-living nematode C. elegans has
contributed as a parasitic model to defining mechanisms of
antiparasitic drug action.
Cys-loop receptors are major targets of anthelmintic drugs
in parasites and C. elegans (Holden-Dye and Walker, 2006;
Beech and Neveu, 2015). They belong to the family of
pentameric ligand-gated ion channels and play key roles
throughout the nervous system in vertebrates and invertebrates.
They are involved in physiological processes, including muscle
contraction, and are targets for clinically relevant drugs
(Wolstenholme, 2011). In vertebrates, Cys-loop receptors include
acetylcholine nicotinic (nAChRs) and 5-hydroxytryptamine
type 3 (5-HT3) receptors, which are cationic channels, and
GABAA and glycine receptors, which are anionic channels.
C. elegans and parasitic nematode muscle contains two different
types of nAChRs, a levamisole-sensitive (L-AChR) and a
nicotine-sensitive (N-AChR), and a GABA receptor. L-AChRs
mediate muscle contraction whereas GABA receptors mediate
muscle relaxation. These two receptors are essential for the
typical sinusoidal movement and are targets of anthelmintic
compounds, like levamisole and pyrantel (L-AChR agonists)
and piperazine (GABA receptor agonist) (Martin, 1997; Fleming
et al., 1997; Culetto et al., 2004; Towers et al., 2005;
Bamber et al., 2005; Rayes et al., 2007). N-AChR is a
homopentameric receptor that responds to acetylcholine and
nicotine and its role in locomotion is not fully understood
(Touroutine et al., 2005). Compared to vertebrates, invertebrates
contain a larger variety of Cys-loop receptors, including a
unique type of glutamate-gated chloride channels (GluCl)
(Jones and Sattelle, 2008).
GluCls are of considerable medical and economical
importance because they are targets of macrocyclic lactones,
such as ivermectin (IVM), which are the most widely used
antiparasitic drugs (Chen and Kubo, 2018). IVM is used in
veterinary for gastrointestinal roundworms, lungworms, grubs,
sucking lice, and mange mites and in humans for treating filarial
diseases (Campbell, 2012).
There are six C. elegans genes encoding GluCl subunits:
avr-14 (GluClα3 subunit), avr-15 (GluClα2), glc-1 (GluClα1),
glc-2 (GluClβ), glc-3 (GluClα4), and glc-4 (Cully et al., 1994,
1996; Vassilatis et al., 1997; Dent et al., 2000; Horoszok et al.,
2001). Functions associated with GluCls include pharyngeal
pumping, which is required for feeding and maintaining
hydrostatic pressure, and for the regulation of locomotion, and
olfactory and temperature responses (Jones and Sattelle, 2008).
Heterologous expression studies have shown that both GluClα1
and GluClβ subunits form functional homomeric receptors, the
first responding to IVM and the latter to glutamate (Vassilatis
et al., 1997; Li et al., 2002), and that GluClα1/β heteropentamers
respond to both IVM and glutamate (Dent et al., 1997; Degani-
Katzav et al., 2016). The X-ray structure of the homomeric
GluClα has revealed information about the binding sites of the
allosteric agonist IVM, the orthosteric agonist L-glutamate and
the open-channel blocker picrotoxin (Hibbs and Gouaux, 2011).
We have recently synthetized a series of oxygenated tricyclic
compounds and determined their anthelmintic activity by
measuring rapid effects on C. elegans. The exposure to
dibenzo[b,e]oxepin-11(6H)-one (doxepinone) produced a rapid
concentration-dependent decrease of the thrashing rate (IC50
∼300 µM), which is a measure of C. elegans motility
and swimming rate (Buckingham and Sattelle, 2009; Scoccia
et al., 2017). Doxepinone is considered a privileged structure,
which refers to compounds whose scaffolds commonly consist
of a rigid ring, including heteroring systems that present
appended residues in well-defined orientations required for
target recognition (Evans et al., 1988). Through appropriate
functional group modifications, these scaffolds can provide
ligands for a number of functionally and structurally discrete
biological receptors, and have, therefore, attracted interest
across a broad spectrum of sciences from chemistry and
biology to medicine. Because doxepinone is a privileged
structure with potential anthelmintic activity, we here explored
in detail its behavioral effects and deciphered its target
site and mechanism of action on C. elegans as a parasite
model. We propose doxepinone as an attractive scaffold




Dibenzo[b,e]oxepin-11(6H)-one (named as doxepinone) was
synthetized following the protocol developed by our group
(Scoccia et al., 2017 and Supplementary Figure S1). Briefly,
2-(phenoxymethyl) benzoic acid was prepared by treating the
commercially available isobenzofuran-1(3H)-one with sodium
phenoxide, which was obtained by reacting phenol with NaH in
the presence of DMF at reflux. 2-(phenoxymethyl) benzoic acid
was then cyclized by intramolecular acylation from the carboxylic
acid compound by using FeCl2 and dichloromethyl methyl ether
as cooperative system in the presence of dichloromethane at
room temperature. Purity was determined by elemental analysis
and melting point.
L-Glutamic acid monosodium salt hydrate, ivermectin and
dimethyl sulfoxide were from Sigma-Aldrich Chem Co.
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Caenorhabditis elegans Strains and
Culture
Nematode strains used were: N2: Bristol wild type; and
the null mutants of Cys-loop receptor subunits: RB918: acr-
16(ok789); DA1316: avr-14(ad1302);avr-15(ad1051);glc-1(pk54);
CB382: unc-49(e382); CB904: unc-38(e264); MT9668: mod-
1(ok103). All strains were obtained from the Caenorhabditis
Genetic Center, supported by the National Institutes of Health
- Office of Research Infrastructure Programs (P40 OD010440).
Nematodes were maintained at 21◦C using standard culture
methods (Brenner, 1974; Stiernagle, 2006; Hernando et al., 2012,
2019). Assays were carried out following standard protocols
described in WormBook1.
Locomotion and Paralysis Assays
All behavioral assays were done at room temperature (21–23◦C)
and all comparisons were done in parallel. Assays were performed
with young adult hermaphrodite worms from synchronized
plates. For comparison among different drug concentrations
or strains, the assays of the control and different conditions
were performed simultaneously. For each condition, 30 worms
(n = 30) were used in paralysis assays and 20 worms (n = 20) in
thrashes assays. Each condition was evaluated 4 times in different
days with different worm batches and always in parallel with the
control, as described before (Hernando et al., 2012, 2019).
Thrashing assays were performed in 100 µl M9 buffer in the
absence or presence of the drug in a 96-well microliter plate as
described before (Jones et al., 2011). A single thrash was defined
as a change in the direction of bending at the mid body. All assays
were carried out by two independent operators and were blinded
to the sample identities.
Paralysis was determined on agar plates containing the tested
drug at room temperature as described before (Hernando et al.,
2012). Body paralysis was followed by visual inspection at the
indicated time (up to 120 min) and was defined as the lack of
body movement in response to prodding.
For prodding, we used the gentle touch stimulus delivered to
the body with an eyebrow hair, avoiding touching the animals
too near the tip of the head or tail (Hernando et al., 2019). We
evaluated different types of nematode paralysis: flaccid paralysis
in which worms appear lengthened; spastic paralysis in which
worms appear shorter, and stationary paralysis in which worms
are immobile but respond to prodding by contracting body wall
muscle (Kass et al., 1980; Hernando et al., 2019). Videos were
acquired with a digital camera ToupCam UCMOS 05100KPA
(Toup Tek Photonics).
Stock solutions of ivermectin (IVM) and doxepinone were
in dimethyl sulfoxide (DMSO). For all assays, the final
concentration of DMSO was lower than 1%.
Pharyngeal Pumping Measurements
Measurements were performed with young adult worms on agar
plates. Plates contained 1 µM IVM, 50 or 100 µM doxepinone.
DMSO was used as the vehicle and was present in all control
1www.wormbook.org
plates at concentrations lower than 1% v/v. Wild-type and
DA1316 young adult worms were transferred to drug plates and
allowed to remain at 20◦C for a 30 min period. We performed
3 independent whole experiments with different worm batches.
Each experiment included comparison of the effects of drugs on
wild-type and mutant strains in parallel, with n = 14 animals for
each condition in each experiment. The number of contractions
in the terminal bulb of the pharynx (pumps per minute) was
counted using a stereomicroscope at 50×magnification.
Body Length Measurements
Young adult hermaphrodite worms (n = 10 worms for each
condition) were transferred to NGM plates containing 2.5 mM
doxepinone. Vehicle (1% DMSO) was used as a control. After 2 h,
images were acquired with a digital camera ToupCam UCMOS
05100KPA (Toup Tek Photonics) and body length was measured
using FIJI-ImageJ software. Four independent whole experiments
were analyzed in parallel with the controls.
Heterologous Cell Expression of GluCls
GluCls were transiently expressed in BOSC 23 cells, which are
modified HEK 293T cells (Pear et al., 1993). The cDNAs encoding
the C. elegans GluClα1 (containing gfp between transmembrane
domains M3 and M4) and GluClβ subunits, both subcloned into
the pcDNA3.1 vector, were kindly provided by Dr. Paas (Degani-
Katzav et al., 2016). Cells were transfected by calcium phosphate
precipitation with the subunit cDNAs (total 4 µg/35 mm dish) at
a ratio GluClα1:GluClβ 1:1 essentially as described before (Bouzat
et al., 2008; Nielsen et al., 2018). All transfections were carried
out for about 8–12 h in DMEM with 10% fetal bovine serum
and were terminated by exchanging the medium. Cells were used
for whole-cell recordings 2 or 3 days after transfection, time at
which maximal functional expression levels are typically achieved
(Bouzat et al., 2008).
Whole-Cell Recordings From BOSC23
Cells
Macroscopic currents were recorded in the whole-cell
configuration as described previously (Bouzat et al., 2008;
Corradi et al., 2009).
The pipette was filled with intracellular solution (ICS)
containing 134 mM KCl, 5 mM EGTA,1 mM MgCl2, and 10 mM
HEPES (pH 7.3). The extracellular solution (ECS) contained
150 mM NaCl, 0.5 mM CaCl2, and 10 mM HEPES (pH 7.4). After
the whole cell formation, ECS containing the agonist or drug was
rapidly applied using a three-tube perfusion system with elevated
solution reservoirs for gravity-driven flow and switching valves
controlled by a VC3 controller (ALA Scientific). The solution
exchange time was estimated by the open pipette method as
described by Liu and Dilger (1991). This method consists in
applying a pulse of 50% diluted ECS to an open patch pipette,
which produces a sudden change in the current measured by
patch-clamp amplifier. After proper adjustment of the electrode
position, the current jump in our system varied between 0.1 and
1 ms (Corradi et al., 2009; Andersen et al., 2016). The compound
doxepinone was dissolved in ECS from DMSO stock solutions.
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The final concentration of DMSO used to solubilize doxepinone
was lower than 0.2%. To study the modulatory action of
doxepinone, responses were evaluated following co-application
or preincubation protocols. After whole cell formation, 3 mM
glutamate-elicited currents (control currents) were first recorded
by a pulse (6 s) of ECS containing glutamate. The compound
was then co-applied with glutamate (Co-application protocol)
or applied during 1 min in the absence of glutamate before
the second glutamate pulse (Preincubation protocol). For all
experiments, the duration of the glutamate pulse was 6 s and
the time of recording was 8 s. A 60-s wash with ECS alone
allowed total recovery of control currents. The treated currents
were normalized to currents elicited by glutamate alone in the
same cell (control current). At the end of the protocol, the
control current was again tested and the experiments in which the
currents were reduced to more than 80% of the original control
current were discarded.
Currents were filtered at 5 kHz and digitized at 20 kHz
using an Axopatch 200B patch-clamp amplifier (Molecular
Devices, CA, United States) and acquired using WinWCP
software (Strathclyde Electrophysiology Software, University of
Strathclyde, Glasgow, United Kingdom). The recordings were
analyzed using the ClampFit software (Molecular Devices, CA,
United States). Currents were fitted by a single exponential
function according to the equation:
I(t) = I[exp(-t/τd)] + I∞
in which t is time, I is the peak current, I∞ is the steady state
current value, and τd is the decay time constant. Net charge was
calculated by current integration (Andersen et al., 2016). The rise
time (tr10−90%) corresponds to the time taken by the current to
increase from 10 to 90% of its maximal value.
Data and Statistical Analysis
Experimental data are shown as mean ± SD. Statistical
comparisons were done using two-tailed Student’s t-test
for pairwise comparisons or oneway ANOVA followed by
Bonferroni’s post hoc tests for multiple comparisons. All the
tests were performed with SigmaPlot 12.0 (Systat Software,
Inc.). Statistically significance was established at p-values < 0.05
(∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001). Concentration–response
curves were determined by non-linear regression fits to
the Hill equation using Prism 5.0 (GraphPad, San Diego,
CA, United States).
RESULTS





We have previously found that dibenzo[b,e]oxepin-11(6H)-one,
referred to as doxepinone, produced rapid paralysis of C. elegans
in liquid medium (Scoccia et al., 2017). After 10 min exposure,
the compound produced a concentration-dependent decrease of
the thrashing rate (IC50 ∼300 µM) (Scoccia et al., 2017). Because
doxepinone is an interesting synthetic molecule with potential
anthelmintic activity we sought to explore its anthelmintic effects
and identify target sites.
To determine receptor targets involved in the rapid effects of
doxepinone on C. elegans swimming rate, we explored the effects
on selected mutant strains lacking Cys-loop receptors involved
in worm locomotion, which are targets of anthelmintic drugs.
The screening is based on the hypothesis that the absence of the
target site leads to drug resistance and, therefore, in the mutant
worm, the thrashing rate in the presence of doxepinone will
not be affected. Since some mutant strains show uncoordinated
phenotypes, we determined the number of thrashes/min of
wild-type and each mutant strain in liquid medium in the
absence and presence of doxepinone (Figure 1A). For each
strain, 20 worms in each condition were used, and experiments
were repeated with different worm batches and in different
days in four independent assays, always in parallel with the
control condition.
The thrashing rate of wild-type worms in M9 buffer (plus 1%
DMSO) was 204 ± 9.3 min−1 (Figure 1A). After 30 min pre-
exposure to 0.1 mM doxepinone, this rate decreased about 50%
(103 thrashes/min, p < 0.001, Student t-Test) (Figure 1A).
Mutant worms lacking the UNC-38 subunit (CB904 strain),
which is an essential L-AChR subunit, or lacking UNC-49
(GABA) receptors (CB382 strain) showed lower thrashing rates
than wild-type worms as well as uncoordinated phenotypes
(Brenner, 1974, Figure 1A). Nevertheless, doxepinone reduced
the trashing rate in both mutants (Figure 1A, p < 0.001), with
the magnitude of the reduction being similar to that observed
in wild-type worms (Figure 1B). The MT9668 strain lacks the
serotonin-gated chloride channel, MOD-1, that is involved in
locomotion and behavior (Ranganathan et al., 2000; Komuniecki
et al., 2012). This mutant strain was sensitive to the drug
(Figure 1A, p< 0.001), which produced a decrease of the trashing
rate similar to that observed in wild-type worms (Figure 1B).
Thus, L-AChR, UNC-49 and MOD-1 receptors are not the main
receptors involved in the rapid effects of doxepinone in the
swimming rate. The RB918 strain, which lacks the nicotine-
sensitive nAChR (N-AChR) present in muscle (Touroutine
et al., 2005), was also sensitive to doxepinone (Figure 1A,
n = 20 worms for each condition). However, the decrease
of the trashing rate was slightly, but statistically significantly,
lower than that observed for wild-type worms, indicating some
type of contribution of this receptor to doxepinone action
(Figure 1B, p < 0.01).
The thrashing rate of the triple mutant worms lacking three
GluCl subunit genes (DA1316) was similar to that of wild-type
animals in the absence of the drug (Figure 1A). Interestingly,
exposure to 0.1 mM doxepinone did not affect this rate, in
contrast to the effects observed in wild-type worms (Figure 1A,
n = 20, p > 0.05). The percentage of the reduction of the
thrashing rate due to the presence of doxepinone was statistically
significantly different between wild-type and DA1316 worms
(Figure 1B, p < 0.001). Altogether, our results indicate that
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FIGURE 1 | Screening of mutants for resistance to doxepinone. Synchronized
young adult wild-type worms were used. Measurements were performed in
liquid medium after 30 min incubation in M9 buffer containing 1% DMSO in
the absence or presence of 0.1 mM doxepinone. A single thrash was defined
as a change in the direction of bending at the mid body. The non-functional
receptor in each mutant strain is indicated. n = 20 worms per condition,
repeated in 4 different days and worm batches, in parallel with the control.
(A) Bar chart showing the thrashing rate for each mutant in the absence (left
bar) or presence of doxepinone (right bar) for each mutant. Statistical
comparisons were made for each strain in the absence and presence of
doxepinone. (B) Bar chart showing the reduction in the thrashes/min in each
strain due to the presence of doxepinone. ns, non-statistically significant,
**p < 0.01 or ***p < 0.001 respect to the change in the wild-type strain.




To determine the type of paralysis and the contribution of the
different Cys-loop receptors to doxepinone effects, we performed
paralysis assays on agar plates containing the drug.
We first characterized the type of paralysis exerted by
doxepinone by exposing wild-type worms to 2.5 mM doxepinone
for 30–120 min in agar plates. After 60 min exposure, the worms
in the presence of doxepinone were immobile but respond to
prodding by contracting body muscle (Supplementary Video
S1). After 2 h exposure, worms did not show any response and
were completely paralyzed. The length of worms in the absence
of the drug was 1.16 ± 0.01 mm whereas it was 1.10 ± 0.04 mm
after 1 h exposure (n = 10, p > 0.05), indicating neither spastic
nor flaccid paralysis.
For wild-type worms, a clear concentration- and time-
dependent paralysis was detected during the 2 h assay at
a 1–3 mM doxepinone concentration range (Figure 2A). At
the maximum exposure time (2 h), ∼85% adult worms were
paralyzed by 3 mM doxepinone (Figure 2A, n = 30). The IC50
values determined for the inhibition of moving worms in agar
plates were 2.58 ± 0.01 mM and 2.10 ± 0.01 mM for 90 and
120 min exposure, respectively (Figure 2B). Paralysis assays on
agar plates measured at short times usually require higher drug
concentrations than those used in liquid medium probably since
the drug must be absorbed from the solid phase.
To confirm the contribution of the different Cys-loop
receptors to doxepinone effects, we next measured paralysis
as a function of time of different mutant worms exposed
to 2.5 mM doxepinone. We found that the reduction of
moving worms as a function of time of exposure for MT9668,
CB904, and CB382 strains did not differ from that of wild-
type worms (Figure 2C). For these mutants, the fraction of
moving worms was reduced to ∼0.40 after 2 h exposure
on agar plates containing 2.5 mM doxepinone (Figure 2C).
Although slight, there was a statistically significant difference
in the effects of the drug on RB918 worms (lacking N-AChR)
respect to wild-type worms after 2 h exposure (p < 0.01,
n = 30). For worms lacking GluCl subunits (DA1316), only a
slight reduction of the fraction of moving animals was detected
after 2 h exposure to doxepinone (18%). This reduction was
markedly different to that of wild-type worms and other mutants
(∼60%), again indicating that GluCls are involved in doxepinone
paralysis (Figure 2C).
Because GluCls are targets of IVM we compared the effects of
doxepinone with those of IVM on DA1316 (lacking three GluCl
genes) and wild-type strains. After 30 min exposure to 10 µM
IVM in liquid medium, wild-type worms were fully paralyzed
whereas mutant worms (DA1316) showed only 50% reduction
of the thrashing rate (Figure 3A). In agar plates containing 300
µM IVM, wild-type animals showed a time-dependent paralysis
that yielded 80% paralyzed worms after 2 h. On the contrary,
the percentage of paralyzed mutant worms was smaller than
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FIGURE 2 | Fraction of moving animals after exposure to doxepinone as a
function of time and concentration. Synchronized young adult wild-type
worms were placed on agar plates containing DMSO or doxepinone and
observed at the indicated time to determine the fraction of worms that
respond to prodding, which were considered as “moving worms.” The results
correspond to 4 independent assays for all conditions in the figure with 30
worms each time per condition. (A) Wild-type worms were exposed in agar
plates containing doxepinone (1–3 mM range). The fraction of moving animals
was determined at 30 min intervals. (B) Dose-response curves determined on
agar plates for wild-type worms exposed 90 min (gray) or 120 min (black) to
2.5 mM doxepinone. (C) Paralysis as a function of time of exposure of worms
to 2.5 mM doxepinone. Statistical comparisons are made respect to wild-type
strain. **p < 0.01, ***p < 0.001 respect to the change in the wild-type strain.
10% after 2 h (Figure 3B). After 2 h exposure, the difference
in the fraction of moving worms between wild-type and mutant
animals was statistically significative (p < 0.001, n = 30). We also
Time (minutes)
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FIGURE 3 | Effects of ivermectin on wild-type and mutant worms lacking
GluCl genes. Synchronized young adult worms from wild-type worms or
DA1316 strain that lacks GluCl subunit genes. (A) Measurements were
performed in liquid medium after 30 min incubation in M9 buffer plus M9 buffer
containing 1% DMSO in the absence (left bar for each strain) or presence of
10 µM IVM (right bar for each strain). n = 20 worms per condition. The results
correspond to 4 independent assays of the whole experiment shown in the
figure. (B) Percentage of moving worms measured on agar plates as a
function of time of exposure to 300 µM IVM. Statistical comparisons are made
respect to the fraction of wild-type worms. n = 20 worms per condition. The
results correspond to 4 independent assays of the whole experiment shown in
the figure. ***p < 0.001 respect to the change in the wild-type strain.
determined that the type of paralysis of wild-type worms exposed
to 300 µM IVM in agar plates during 60 min was similar to that
observed for doxepinone: worms appeared immobile but respond
to prodding by contracting body muscle (Hernando and Bouzat,
2014; Supplementary Video S2).
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FIGURE 4 | Ivermectin and doxepinone effects on pharyngeal pumping.
Wild-type and DA1316 young adult worms were transferred to
bacteria-seeded NGM plates containing different concentration of IVM and
doxepinone (IVM = 1.0 µM, doxepinone = 50 and 100 µM). After 30 min of
drug exposure, the number of contractions in the terminal bulb of the pharynx
(pumps) was counted using a stereomicroscope at 50x magnification. Bars
represent the mean ± SD from n = 14 animals per condition. Statistical
differences compared to the non-treated condition of the same strain
(***p < 0.001). The symbol # indicates statistically significant differences
between the two strains at the same condition (###p < 0.001).
3-Doxepinone Reduces Pharyngeal
Pumping Rate
One of the hallmark effects of IVM involving GluCls is
pharyngeal pumping inhibition (Dent et al., 1997, 2000).
We therefore evaluated the effects of doxepinone on
the pharyngeal pumping rate of wild-type and mutant
worms lacking GluCl subunit genes (DA1316). In the
absence of drugs, wild-type and DA1316 worms showed
similar pumping rates of ∼180–200 min−1 (Figure 4).
It is important to note that despite lacking GluCls the
mutant worms show normal pumping due to compensatory
effects and that IVM also affects other Cys-loop receptors
(Pemberton et al., 2001; Lynagh and Lynch, 2012;
Trojanowski et al., 2016).
The exposure of worms to 1 µM IVM decreased 4-fold
the pumping rate in wild-type worms and about 1.7-fold in
DA1316 worms (n = 14, p < 0.001) (Figure 4). These results
confirmed that worms lacking GluCl subunits are more resistant
to the pumping rate inhibition by IVM than wild-type animals
(Figure 4). In wild-type animals, increasing concentrations
of doxepinone produced a monotonically decrease of the
pharyngeal pumping rate, which was reduced 4-fold at 50
µM and 100% at 100 µM (Figure 4). On the contrary, only
∼1.5-fold reduction was observed in the DA1316 worms in
the presence of 100 µM doxepinone with respect to the
control, thus indicating that the mutants are resistant to the
pharyngeal pumping effect of doxepinone (Figure 4). Thus,
the actions of doxepinone correlate with those of IVM and
depend on GluCls.
4-Molecular Actions of Doxepinone on
GluCls
To confirm that doxepinone acts at GluCls and to unravel
the mechanism by which it may affect these receptors, we
expressed GluClα1/β in BOSC 23 cells and measured whole-
cell currents at −60 mV holding potential. Currents were
elicited by rapid application of 3 mM glutamate, which is a
concentration higher than its EC50 for these receptors (∼1.5 mM)
but lower than that required for saturation (Cully et al., 1994;
Degani-Katzav et al., 2016).
A 6-s pulse of 3 mM glutamate in ECS elicited
macroscopic currents that reached the peak with a rise
time of 49.30 ± 16.20 ms (n = 9) and decayed in the
presence of the agonist due to desensitization. Typically,
peak currents varied between 2000 and 7000 pA. The decay
was fitted by a single component with a time constant of
2100 ± 1040 ms (n = 9). The application of another pulse of
glutamate after a 20-s wash with ECS allowed full recovery
of the peak current, indicating that most receptors recovered
from desensitization in the absence of the agonist after this
period (Figure 5A).
To further characterize GluCl-mediated currents, we
constructed current-voltage relationships by measuring the
peak current elicited by 3 mM glutamate as a function of the
holding potential (Figure 5B). As shown in the figure, the
magnitude of GluCl-elicited currents increased linearly with the
voltage, indicating an ohmic behavior, and currents did not show
important rectification (n = 4).
We next proceeded to decipher the molecular actions
of doxepinone at GluCls. To first determine if doxepinone
can activate GluCls, a 6-s pulse of 0.5 mM doxepinone
(n = 7) or 1 mM doxepinone (n = 3) was applied to cells
in the whole-cell configuration at -60 mV. No currents
were elicited by doxepinone and sequential application
of 3 mM glutamate to the same cell elicited macroscopic
responses, indicating the presence of functional GluCls
(Figure 5C). Thus, doxepinone does not act as an
agonist of GluCls.
We next evaluated the action of doxepinone as a
modulator of glutamate-activated currents. To this end,
we used two different drug application protocols, one
including preincubation of the drug before glutamate
application (Preincubation protocol) and the other, application
of doxepinone together with glutamate (Co-application
protocol).
For the preincubation protocol, a pulse of ECS containing
3 mM glutamate (6 s-pulse, control current) was first applied
to the cell held at -60 mV, and the cell was incubated during
1 min with ECS containing doxepinone (1 mM) before a second
pulse of ECS-glutamate was applied (treated) (Figure 6A). The
same protocol was repeated three times in the same cell, each
time separated by a 60-s period. An illustrative example of
an experiment from a single cell is shown in Figures 6A,B.
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FIGURE 5 | Macroscopic responses of GluClα1/β receptors heterologously expressed in mammalian cells. (A) Macroscopic currents elicited by 3 mM glutamate in
the whole-cell configuration. Representative responses to glutamate in a single cell. Cells were first exposed to a 6-s pulse of 3 mM glutamate, then to a 20-s pulse
of ECS alone, and finally again to the 3 mM glutamate-containing ECS. Pipette potential: -60 mV. (B) Left: currents elicited by 6 s -pulse of 3 mM glutamate at
different pipette potentials (from 100 to -100 mV, Vm). Right: Current (I)-Voltage (Vm) relationship for GluCl channels under symmetrical chloride solutions (n = 4). (C)
Cells were first exposed to a 6-s pulse of 3 mM glutamate (black line current), then to a 6-s pulse of 1 mM doxepinone (violet line current), and finally again to the
3 mM glutamate-containing ECS to verify current recovery. Pipette potential: −60 mV.
The results from different cells were averaged and shown in
Figure 6C.
Preincubation of the cell with 1 mM doxepinone produced
a slight decrease of the peak current and a profound decrease
of the current decay time constant and net charge (Figure 6C).
Compared to the corresponding control current in each cell,
the peak current was reduced to 0.81 ± 0.08 (p = 0.001), the
decay rate to 0.57 ± 0.13 (p = 0.001), and the net charge
to 0.49 ± 0.11 (p = 0.002, n = 6). Thus, the main effect of
the drug on glutamate-elicited currents is the increase in the
decay rate (or decrease of the decay time constant), which
leads to a concomitant decrease in the net charge. We also
determined that the percentage of changes after drug application
were similar among the three applications on each cell. Also, no
significant differences were found in the relative peak current
(1.01 ± 0.10), net charge (0.99 ± 0.17), and decay time constant
(0.95± 0.06) with respect to the control when preincubation was
performed with 0.2% DMSO in ECS in the absence of doxepinone
(n = 4).
We also explored if doxepinone applied together with
glutamate (co-application protocol) affected GluCl currents
(Figures 6E,D). In each cell, we applied three pulses of
glutamate containing ECS, each one separated by 20 s,
and then three pulses of ECS containing 3 mM glutamate
and 1 mM doxepinone (Figure 6D). Doxepinone did
not produce statistically significant changes in the peak
currents (0.99 ± 0.02, p = 0.319) but produced a slight
and statistically significantly decrease of the net charge
(0.83 ± 0.06, p = 0.001) and decay time constant (0.76 ± 0.10,
p = 0.008) (n = 5 cells) (Figure 6E). Thus, co-application
of doxepinone inhibited glutamate-activated currents but
the changes were smaller than those determined under the
preincubation protocol.
DISCUSSION
We here identified dibenzo[b,e]oxepin-11(6H)-one (doxepinone)
as a novel anthelmintic compound acting through GluCls by
a different mechanism to that of the widely used anthelmintic
drug, IVM, and proposed that GluCl inhibition may be further
explored as a mechanism of action of anthelmintic drugs.
The anthelmintic action of doxepinone is revealed by
the induction of worm paralysis measured in agar plates,
the inhibition of worm mobility in liquid medium, and an
important decrease of the pumping rate. Because rapid effects
as the ones observed for doxepinone may be mediated by
ion channels, we performed the first screening for resistance
to doxepinone on selected null mutant strains lacking Cys-
loop receptors involved in worm locomotion. The screening
identified GluCls, which are main receptor targets of IVM, as
targets of doxepinone. In close agreement with this finding,
we demonstrated that the effects of doxepinone recapitulate
those of IVM. Particularly, the inhibition of the pumping rate
is a hallmark of IVM action. Also, the paralysis induced by
doxepinone is neither spastic nor flaccid as that observed in the
presence of IVM.
Our screening showed that N-AChRs may play a role in the
paralysis caused by doxepinone since the worms lacking the ACR-
16 subunit are less sensitive to the drug than wild-type worms.
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FIGURE 6 | Effects of doxepinone on glutamate-elicited responses using different application protocols. Doxepinone (1 mM) was applied before the 3 mM glutamate
pulse (preincubation, ± protocol) or together with glutamate (co-application, −/ + protocol). Pipette potential: −60 mV. (A) ± protocol: 6 s-pulse of 3 mM glutamate
was applied before (control current, c) and after (treated current, t) preincubation during 60 s with 1 mM doxepinone. Currents were recorded after 1 min wash with
ECS to confirm recovery (recovered, w). This protocol was repeated 3 times in each cell. (B) Illustrative example of the changes in the macroscopic current
parameters obtained after each application of 3 mM glutamate in a single cell with the protocol shown in (A). c, control current; t and w, correspond to the
glutamate-activated current obtained after 60-s incubation with 1 mM doxepinone (treated, t) or buffer alone (wash, w). The sub index corresponds to the
agonist-application order in the series. (C) Bar chart showing the averaged changes in peak current, decay time constant and net charge due to the preincubation
with 1 mM doxepinone (t). For each experiment, the peak current, the decay time constant and total area were related to those of the control current in each cell (c).
The values correspond to the mean of 6 different cells and 4 different days of transfection (***p < 0.001; **p < 0.01). (D) −/ + protocol: 6 s-pulse of 3 mM glutamate
was first applied alone (control current, black line) and then together with 1 mM doxepinone (treated current, violet line). (E) Bar chart showing the effects of 3 mM
glutamate/1 mM doxepinone co-application on peak current, decay time constant and net charge. The values correspond to the mean ± SD of 5 different cells
(***p < 0.001; **p < 0.01; *p < 0.05).
However, the effect is not as relevant as that mediated by GluCls.
Also, we cannot discard that other receptors, not explored here,
may be involved in doxepinone effects on C. elegans. Finally,
it would be also interesting to perform studies on parasitic
nematodes to confirm that they respond to doxepinone similarly
to the free-living nematode.
Inhibitory GluCls are expressed on neurons and muscle
across protostome phyla, including mollusks, flatworms,
nematodes, ticks, and mites, as well as insects and crustaceans
(Wolstenholme, 2012). They are of great importance since
they are one of the main target sites for parasitic control.
IVM and macrocyclic lactones are used to eliminate
nematode infections from millions of humans suffering
from diseases, such as river blindness and lymphatic filariasis,
and are also used in domestic pets and cattle for parasitic
nematodes and ectoparasites (Omura, 2008). GluCls in
Anopheles gambiae sensu stricto were also proposed as
targets of IVM to control malaria (Meyers et al., 2015;
Atif et al., 2019).
In C. elegans, the expression pattern of the different GluCl
genes has been explored (Holden-Dye and Walker, 2014). In
particular, GluClα1 subunit expresses in body wall muscle, head
neurons, and pharyngeal muscle cells and GluClβ subunit in
pharyngeal muscle pm4 cells. Although GluCl subunits can form
homomeric or heteromeric receptors in heterologous expression
systems, the composition of the native receptors remains mostly
unknown. To elucidate the molecular functional consequences of
doxepinone acting at GluCls, we used as a model the GluClα1/β
receptor, which has been previously characterized in detail in
mammalian cells (Degani-Katzav et al., 2016). Since the DA1316
strain lacks three GluCl genes, avr-14, avr-15, and glc-1, it would
be interesting to explore in future work the molecular effects of
doxepinone on other GluCl subtypes (Brockie and Maricq, 2006).
Cells expressing GluClα1/β receptors displayed robust
responses to 3 mM glutamate, in line with previous findings
(Degani-Katzav et al., 2016). By analyzing the peak current as a
function of voltage we determined that the ion channel has an
ohmic behavior with no significant rectification.
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Currents could not be elicited by the solely application of
doxepinone, indicating that it is not an agonist of this type
of GluCl, an action distinct from that exerted by IVM. Pre-
exposure of GluCls to doxepinone before activation with the
agonist significantly decreased the net charge, thus revealing
that doxepinone acts as an inhibitor. The analysis of current
parameters showed a slight decrease of the peak current and a
significant increase of the current decay rate, indicating that this
latter change governs the negative modulation. The changes are
qualitatively similar but quantitatively smaller when doxepinone
is applied together with glutamate with no preincubation.
Receptor inhibition may be caused by competitive or non-
competitive antagonism. If inhibition were due to competitive
antagonism, a reduction of the peak current instead of an increase
in the decay rate would be observed. Also, the effects produced
by co-application of doxepinone with glutamate would be greater
than those observed with preincubation, which is opposite to our
experimental results. Thus, our first molecular characterization
suggests that doxepinone acts as a negative allosteric modulator
(non-competitive antagonist) of GluCl. The enhancement of the
current decay rate due to the presence of allosteric inhibitors
may arise from enhanced desensitization or channel block
(Gumilar et al., 2003). However, further electrophysiological
characterization, including competition studies, is required to
unequivocally define its mechanism of action as well as its
potential binding sites at GluCl.
The three-dimensional atomic structure of the homomeric
C. elegans GluClα shows that IVM occupies a cavity between
adjacent subunits in the transmembrane domain (Hibbs and
Gouaux, 2011). Further studies combining mutant receptors may
help to define if doxepinone binds to the IVM site.
Although sharing the target receptor, IVM and doxepinone
are non-related, structurally different compounds. Whereas IVM
is a high molecular weight macrocyclic lactone derived from
avermectins, doxepinone constitutes a class of fused tricyclic
heterocycles present in a variety of bioactive compounds.
Structurally, it is typified by the presence of a dibenzo-4-
oxepanone ring system. Each ring is connected in a fused
formation that does not allow rotation around the carbon-
carbon bonds. This unique structure together with the type
and position of the linked chemical groups define the
specific functionalities of doxepinone. The hydrophobic planar
architecture of this oxygenated heterocyclic gives it a remarkably
different physicochemical behavior with respect to IVM.
The structure of doxepinone is related to that of
tricyclic antidepressants, in particular to doxepin. Tricyclic
antidepressants have been shown to inhibit other Cys-loop
receptors, including vertebrate nAChR and 5-HT3A receptors
(Gumilar et al., 2003; Gumilar and Bouzat, 2008). Doxepin
reduced the peak current and increased the decay rate of mouse
muscle nAChRs; these effects were greater when applied during
preincubation than co-applied with the agonist (Gumilar et al.,
2003). Enhancement of desensitization and/or slow channel
blockade was proposed as the mechanism underlying the
macroscopic effects (Gumilar et al., 2003). Although we have
shown previously that doxepin slightly decreased the thrashing
rate in C. elegans, the effect was significantly lower compared
to that of doxepinone (Scoccia et al., 2017). Interesting, it has
been reported that doxepin shows anthelmintic activity against
the intestinal helminth Ancylostoma ceylanicum, revealing an
antiparasitic action (Keiser et al., 2016).
The widely use of IVM has resulted in selection of resistant
parasitic nematodes, which has turned into a major global
problem (Laing et al., 2017). It has also raised concerns
that IVM resistance may evolve in human parasites as well
(Laing et al., 2017). Mechanisms underlying IVM resistance
include changes in sequence and composition of GluCls and in
proteins regulating membrane permeability and gap junctions.
Importantly associated to IVM resistance is the enhanced
expression of the multidrug transport protein, P-glycoprotein,
involved in drug exclusion (Blackhall et al., 1998; Xu et al.,
1998; Le Jambre et al., 1999; Sangster et al., 1999; Ardelli
and Prichard, 2013; Ménez et al., 2016). Since IVM and
doxepinone are structurally different compounds, they will
probably show different activities at P-glycoprotein as well as
different sensitivities among GluCl subtypes. Thus, our finding
offers a new scaffold for developing new GluCl-active compounds
directed to overcome IVM resistance as well as to cover different
helminth species.
The effect of IVM and macrocyclic lactones has been proposed
to be mediated by increased hyperpolarization due to its agonistic
activity at chloride permeable GluCls. We here found that
doxepinone has the opposite effect. Therefore, the inhibition of
GluCls emerges as an anthelmintic mechanism of action. In line
with this, for several insecticides, such as picrotoxin, lindane, and
fipronil, the inhibition through GluCl has been proposed as a
mechanism involved in their insecticide actions (Narahashi et al.,
2010; Atif et al., 2019). Fipronil has been shown to reversibly
inhibit GluCls from C. elegans (Horoszok et al., 2001) and from
Haemonchus contortus (McCavera et al., 2009) and it has been
shown to be effective for controlling nematodes on wheat (Cui
et al., 2017). Thus, it appears that both enhanced and reduced
hyperpolarization can affect worm locomotion and pharyngeal
pumping. How neuron wiring underlying the behavioral effects
is affected as a result of reduced hyperpolarization due to
GluCl inhibition is therefore an essential question for future
studies. Overall, we propose doxepinone as a new scaffold
with potential antiparasitic activity and the inhibition of GluCls
as a mechanism of anthelmintic drug action valuable to be
further explored.
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FIGURE S1 | Total synthesis of doxepinone. Conditions: (A) NaH (1.5 equiv), DMF
(dimethylformamide), reflux, 24 h; then conc. HCl; (B) FeCl2 (0.6 equiv), DCME
(dichloromethyl methyl ether) (1 equiv), DCM (dichloromethane) (0.1 M), rt. Isolated
yield (%) after purification. The details of the procedure have been described
in Scoccia et al. (2017).
VIDEO S1 | Wild-type worms exposed to 2.5 mM doxepinone in agar plates. The
worms are immobile but respond to prodding by contracting body muscles.
VIDEO S2 | Wild-type worms exposed to 300 µM IVM in agar plates. The worms
are immobile but respond to prodding by contracting body muscles.
REFERENCES
Andersen, N. D., Nielsen, B. E., Corradi, J., Tolosa, M. F., Feuerbach, D., Arias,
H. R., et al. (2016). Exploring the positive allosteric modulation of human α7
nicotinic receptors from a single-channel perspective. Neuropharmacology 107,
189–200. doi: 10.1016/j.neuropharm.2016.02.032
Angstadt, J. D., Donmoyer, J. E., and Stretton, A. O. (1989). Retrovesicular ganglion
of the nematode Ascaris. J. Comp. Neurol. 284, 374–388. doi: 10.1002/cne.
902840305
Ardelli, B. F., and Prichard, R. K. (2013). Inhibition of P-glycoprotein enhances
sensitivity of Caenorhabditis elegans to ivermectin. Vet. Parasitol. 191, 264–275.
doi: 10.1016/j.vetpar.2012.09.021
Atif, M., Lynch, J. W., and Keramidas, A. (2019). The effects of insecticides on
two splice variants of the glutamate-gated chloride channel receptor of the
major malaria vector, Anopheles gambiae. Br. J. Pharmacol. 177, 175–187. doi:
10.1111/bph.14855
Bamber, B. A., Richmond, J. E., Otto, J. F., and Jorgensen, E. M. (2005).
The composition of the GABA receptor at the Caenorhabditis elegans
neuromuscular junction. Br. J. Pharmacol. 144, 502–509. doi: 10.1038/sj.bjp.
0706052
Beech, R. N., and Neveu, C. (2015). The evolution of pentameric ligand-gated ion-
channels and the changing family of anthelmintic drug targets. Parasitology 142,
303–317. doi: 10.1017/S003118201400170X
Blackhall, W. J., Liu, H. Y., Xu, M., Prichard, R. K., and Beech, R. N. (1998).
Selection at a P-glycoprotein gene in ivermectin- and moxidectin-selected
strains of Haemonchus contortus. Mol. Biochem. Parasitol. 95, 193–201. doi:
10.1016/s0166-6851(98)00087-5
Bouzat, C., Bartos, M., Corradi, J., and Sine, S. M. (2008). The interface between
extracellular and transmembrane domains of homomeric Cys-loop receptors
governs open-channel lifetime and rate of desensitization. J. Neurosci. 28,
7808–7819. doi: 10.1523/JNEUROSCI.0448-08.2008
Brenner, S. (1974). The genetics of Caenorhabditis elegans. Genetics 77,
71–94.
Brockie, P. J., and Maricq, A. V. (2006). Ionotropic glutamate receptors:
genetics, behavior and electrophysiology. WormBook 2006, 1–16. doi: 10.1895/
wormbook.1.61.1
Buckingham, S. D., and Sattelle, D. B. (2009). Fast, automated measurement of
nematode swimming (thrashing) without morphometry. BMC Neurosci. 10:84.
doi: 10.1186/1471-2202-10-84
Campbell, W. C. (2012). History of avermectin and ivermectin, with notes on
the history of other macrocyclic lactone antiparasitic agents. Curr. Pharm.
Biotechnol. 13, 853–865. doi: 10.2174/138920112800399095
Chen, I.-S., and Kubo, Y. (2018). Ivermectin and its target molecules: shared and
uniquemodulation mechanisms of ion channels, and receptors by ivermectin.
J. Physiol. 596, 1833–1845. doi: 10.1113/JP275236
Corradi, J., Gumilar, F., and Bouzat, C. (2009). Single-channel kinetic analysis for
activation and desensitization of homomeric 5-HT(3)A receptors. Biophys. J.
97, 1335–1345. doi: 10.1016/j.bpj.2009.06.018
Cui, J. K., Huang, W. K., Peng, H., Lv, Y., Kong, L. A., Li, H. X., et al. (2017). Efficacy
evaluation of seed-coating compounds against cereal cyst nematodes and root
lesion nematodes on wheat. Plant Dis. 101, 428–433. doi: 10.1094/PDIS-06-16-
0862-RE
Culetto, E., Baylis, H. A., Richmond, J. E., Jones, A. K., Fleming, J. T., Squires,
M. D., et al. (2004). The Caenorhabditis elegans unc-63 Gene Encodes a
Levamisole sensitive Nicotinic Acetylcholine Receptor α Subunit. J. Biol. Chem.
279, 42476–42483. doi: 10.1074/jbc.M404370200
Cully, D. F., Paress, P. S., Liu, K. K., Schaeffer, J. M., and Arena, J. P. (1996).
Identification of a Drosophila melanogaster glutamate gated chloride channel
sensitive to the antiparasitic agent avermectin. J. Biol. Chem. 271, 20187–20191.
doi: 10.1074/jbc.271.33.20187
Cully, D. F., Vassilatis, D. K., Liu, K. K., Paress, P. S., Van der Ploeg, L. H.,
Schaeffer, J. M., et al. (1994). Cloning of an avermectin-sensitive glutamate-
gated chloride channel from Caenorhabditis elegans. Nature 371, 707–711. doi:
10.1038/371707a0
Degani-Katzav, N., Gortler, R., Gorodetzki, L., and Paas, Y. (2016). Subunit
stoichiometry and arrangement in a heteromeric glutamate-gated chloride
channel. Proc. Natl. Acad. Sci. U.S.A. 113, E644–E653. doi: 10.1073/pnas.
1423753113
Dent, J. A., Davis, M. W., and Avery, L. (1997). avr-15 encodes a chloride
channel subunit that mediates inhibitory glutamatergic neurotransmission and
ivermectin sensitivity in Caenorhabditis elegans. EMBO J. 16, 5867–5879. doi:
10.1093/emboj/16.19.5867
Dent, J. A., Smith, M. M., Vassilatis, D. K., and Avery, L. (2000). The genetics of
ivermectin resistance in Caenorhabditis elegans. Proc. Natl. Acad. Sci. U.S.A. 97,
2674–2679. doi: 10.1073/pnas.97.6.2674
Evans, B. E., Rittle, K. E., Bock, M. G., DiPardo, R. M., Freidinger, R. M.,
Whitter, W. L., et al. (1988). Methods for drug discovery: development of
potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem. 31,
2235–2246. doi: 10.1021/jm00120a002
Fleming, J. T., Squire, M. D., Barnes, T. M., Tornoe, C., Matsuda, K., Ahnn, J., et al.
(1997). Caenorhabditis elegans levamisole resistance genes lev-1, unc-29 and
unc-38 encode functional nicotinic acetylcholine receptor subunits. J. Neurosci.
17, 5843–5857.
Gumilar, F., Arias, H. R., Spitzmaul, G., and Bouzat, C. (2003). Molecular
mechanisms of inhibition of nicotinic acetylcholine receptors by tricyclic
antidepressants. Neuropharmacology 45, 964–976. doi: 10.1016/s0028-3908(03)
00247-8
Gumilar, F., and Bouzat, C. (2008). Tricyclic antidepressants inhibit homomeric
Cys-loop receptors by acting at different conformational states. Eur. J.
Pharmacol. 584, 30–39. doi: 10.1016/j.ejphar.2008.01.023
Hernando, G., Berge, I., Rayes, D., and Bouzat, C. (2012). Contribution of subunits
to Caenorhabditis elegans levamisole-sensitive nicotinic receptor function. Mol.
Pharmacol. 82, 550–560. doi: 10.1124/mol.112.079962
Hernando, G., and Bouzat, C. (2014). Caenorhabditis elegans neuromuscular
junction: GABA receptors and ivermectin action. PLoS One 9:e95072. doi:
10.1371/journal.pone.0095072
Frontiers in Neuroscience | www.frontiersin.org 11 August 2020 | Volume 14 | Article 879
fnins-14-00879 August 17, 2020 Time: 16:35 # 12
Castro et al. GluCls as Drug Targets
Hernando, G., Turani, O., and Bouzat, C. (2019). Caenorhabditis elegans muscle
Cys-loop receptors as novel targets of terpenoids with potential anthelmintic
activity. PLoS Negl. Trop. Dis. 13:e0007895. doi: 10.1371/journal.pntd.0007895
Hibbs, R. E., and Gouaux, E. (2011). Principles of activation and permeation
in an anion-selective Cys-loop receptor. Nature 474, 54–60. doi: 10.1038/
nature10139
Holden-Dye, L., and Walker, R. J. (2006). Actions of glutamate and ivermectin
on the pharyngeal muscle of Ascaridia galli: a comparative study with
Caenorhabditis elegans. Int. J. Parasitol. 36, 395–402. doi: 10.1016/j.ijpara.2005.
11.006
Holden-Dye, L., and Walker, R. J. (2007). Anthelmintic drugs. WormBook 2, 1–13.
doi: 10.1895/wormbook.1.143.1
Holden-Dye, L., and Walker, R. J. (2014). Anthelmintic drugs and nematicides:
studies inCaenorhabditis elegans.WormBook 16, 1–29. doi: 10.1895/wormbook.
1.143.2
Horoszok, L., Raymond, V., Sattelle, D. B., and Wolstenholme, A. J. (2001). GLC-3:
a novel fipronil and BIDN-sensitive, but picrotoxinin-insensitive, L-glutamate-
gated chloride channel subunit from Caenorhabditis elegans. Br. J. Pharmacol.
132, 1247–1254. doi: 10.1038/sj.bjp.0703937
Jones, A. K., Rayes, D., Al-Diwani, A., Maynard, T. P., Jones, R., Hernando, G., et al.
(2011). A Cys-loop mutation in the Caenorhabditis elegans nicotinic receptor
subunit UNC-63 impairs but does not abolish channel function. J. Biol. Chem.
286, 2550–2558. doi: 10.1074/jbc.M110.177238
Jones, A. K., and Sattelle, D. B. (2008). The cys-loop ligand-gated ion channel
gene superfamily of the nematode, Caenorhabditis elegans. Invert. Neurosci. 8,
41–47.
Kass, I. S., Wang, C. C., Walrond, J. P., and Stretton, A. O. (1980). Avermectin B1a,
a paralyzing anthelmintic that affects interneurons and inhibitory motoneurons
in Ascaris. Proc. Natl. Acad. Sci. U.S.A. 77, 6211–6215. doi: 10.1073/pnas.77.10.
6211
Keiser, J., Panic, G., Adelfio, R., Cowan, N., Vargas, M., and Scandale, I. (2016).
Evaluation of an FDA approved library against laboratory models of human
intestinal nematode infections. Parasit. Vectors 9:376. doi: 10.1186/s13071-016-
1616-0
Komuniecki, R., Law, W. J., Jex, A., Geldhof, P., Gray, J., Bamber, B., et al. (2012).
Monoaminergic signalling as a target for anthelmintic drug discovery: receptor
conservation among the free-living and parasitic nematodes. Mol. Biochem.
Parasitol. 183, 1–7. doi: 10.1016/j.molbiopara.2012.02.001
Laing, R., Gillan, V., and Devaney, E. (2017). Ivermectin - Old Drug. New Tricks?
Trends Parasitol. 33, 463–472. doi: 10.1016/j.pt.2017.02.004
Le Jambre, L. F., Lenane, I. J., and Wardrop, A. J. (1999). A hybridization technique
to identify anthelmintic resistance genes in Haemonchus. Int. J. Parasitol. 29,
1979–1985. doi: 10.1016/s0020-7519(99)00157-5
Li, P., Slimko, E. M., and Lester, H. A. (2002). Selective elimination of glutamate
activation and introduction of fluorescent proteins into a Caenorhabditis
elegans chloride channel. FEBS Lett. 528, 77–82. doi: 10.1016/s0014-5793(02)
03245-3
Liu, Y., and Dilger, J. P. (1991). Opening rate of acetylcholine receptor channels.
Biophys. J. 60, 424–432. doi: 10.1016/S0006-3495(91)82068-9
Lynagh, T., and Lynch, J. W. (2012). Ivermectin binding sites in human and
invertebrate Cys-loop receptors. Trends Pharmacol. Sci. 33, 432–441. doi: 10.
1016/j.tips.2012.05.002
Martin, R. J. (1997). Modes of action of anthelmintic drugs. Vet. J. 154, 11–34.
doi: 10.1016/s1090-0233(05)80005-x
McCavera, S., Rogers, A. T., Yates, D. M., Woods, D. J., and Wolstenholme, A. J.
(2009). An ivermectin-sensitive glutamate-gated chloride channel from the
parasitic nematode Haemonchus contortus. Mol. Pharmacol. 75, 1347–1355.
doi: 10.1124/mol.108.053363
Ménez, C., Alberich, M., Kansoh, D., Blanchard, A., and Lespine, A. (2016).
Acquired tolerance to ivermectin and moxidectin after drug selection pressure
in the nematode Caenorhabditis elegans. Antimicrob. Agents Chemother. 60,
4809–4819. doi: 10.1128/AAC.00713-16
Meyers, J. I., Gray, M., Kuklinski, W., Johnson, L. B., Snow, C. D., Black, W. C.,
et al. (2015). Characterization of the target of ivermectin, the glutamate-gated
chloride channel, from Anopheles gambiae. J. Exp. Biol. 218(Pt 10), 1478–1486.
doi: 10.1242/jeb.118570
Narahashi, T., Zhao, X., Ikeda, T., Salgado, V. L., and Yeh, J. Z. (2010). Glutamate-
activated chloride channels: unique fipronil targets present in insects but not
in mammals. Pestic. Biochem. Physiol. 97, 149–152. doi: 10.1016/j.pestbp.2009.
07.008
Nielsen, B. E., Minguez, T., Bermudez, I., and Bouzat, C. (2018). Molecular
function of the novel α7β2 nicotinic receptor. Cell. Mol. Life Sci. 75, 2457–2471.
doi: 10.1007/s00018-017-2741-4
Omura, S. (2008). Ivermectin: 25 years and still going strong. Int. J. Antimicrob.
Agents 31, 91–98. doi: 10.1016/j.ijantimicag.2007.08.023
Pear, W. S., Nolan, G. P., Scott, M. L., and Baltimore, D. (1993). Production of
high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad.
Sci. U.S.A. 90, 8392–8396. doi: 10.1073/pnas.90.18.8392
Pemberton, D. J., Franks, C. J., Walker, R. J., and Holden-Dye, L. (2001).
Characterization of glutamate-gated chloride channels in the pharynx of wild-
type and mutant Caenorhabditis elegans delineates the role of the subunit
GluCl-2 in the function of the native receptor. Mol. Pharmacol. 59, 1037–1043.
doi: 10.1124/mol.59.5.1037
Ranganathan, R., Cannon, S. C., and Horvitz, H. R. (2000). MOD-1 is a serotonin-
gated chloride channel that modulates locomotory behaviour in C.elegans.
Nature 408, 470–475. doi: 10.1038/35044083
Rayes, D., Flamini, M., Hernando, G., and Bouzat, C. (2007). Activation of
single nicotinic receptor channels from Caenorhabditis elegans muscle. Mol.
Pharmacol. 71, 1407–1415. doi: 10.1124/mol.106.033514
Sangster, N. C., Bannan, S. C., Weiss, A. S., Nulf, S. C., Klein, R. D., and Geary,
T. G. (1999). Haemonchus contortus: sequence heterogeneity of internucleotide
binding domains from P-glycoprotein. Exp. Parasitol. 91, 250–257. doi: 10.1006/
expr.1998.4373
Scoccia, J., Castro, M. J., Faraoni, M. B., Bouzat, C., Martín, V. S., and Gerbino,
D. C. (2017). Iron (II) promoted direct synthesis of dibenzo[b,e]oxepin-
11(6H)-one derivatives with biological activity. A short synthesis of doxepin.
Tetrahedron 73, 2913–2922. doi: 10.1016/j.tet.2017.03.085
Stiernagle, T. (2006). Maintenance of C. elegans. WormBook 1–11. doi: 10.1895/
wormbook.1.101.1
Touroutine, D., Fox, R. M., Von Stetina, S. E., Burdina, A., Miller, D. M. III, and
Richmond, J. E. (2005). acr-16 encodes an essential subunit of the levamisole-
resistant nicotinic receptor at the Caenorhabditis elegans neuromuscular
junction. J. Biol. Chem. 280, 27013–27021. doi: 10.1074/jbc.M502818200
Towers, P. R., Edwards, B., Richmond, J. E., and Sattelle, D. B. (2005).
The Caenorhabditis elegans lev-8 gene encodes a novel type of nicotinic
acetylcholine receptor alpha subunit. J. Neurochem. 93, 1–9. doi: 10.1111/j.
1471-4159.2004.02951.x
Trojanowski, N. F., Raizen, D. M., and Fang-Yen, C. (2016). Pharyngeal pumping
in Caenorhabditis elegans depends on tonic and phasic signaling from the
nervous system. Sci. Rep. 6:22940. doi: 10.1038/srep22940
Vassilatis, D. K., Arena, J. P., Plasterk, R. H., Wilkinson, H. A., Schaeffer, J. M.,
Cully, D. F., et al. (1997). Genetic and biochemical evidence for a novel
avermectin-sensitive chloride channel in Caenorhabditis elegans. Isolation and
characterization. J. Biol. Chem. 272, 33167–33174. doi: 10.1074/jbc.272.52.
33167
Wolstenholme, A. J. (2011). Ion channels and receptor as targets for the control of
parasitic nematodes. Int. J. Parasitol. Drugs Drug Resist. 1, 2–13. doi: 10.1016/j.
ijpddr.2011.09.003
Wolstenholme, A. J. (2012). Glutamate-gated chloride channels. J. Biol. Chem. 287,
40232–40238. doi: 10.1074/jbc.R112.406280
Xu, M., Molento, M., Blackhall, W., Ribeiro, P., Beech, R., and Prichard, R.
(1998). Ivermectin resistance in nematodes may be caused by alteration of
P-glycoprotein homolog. Mol. Biochem. Parasitol. 91, 327–335. doi: 10.1016/
s0166-6851(97)00215-6
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Castro, Turani, Faraoni, Gerbino and Bouzat. This is an open-
access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Neuroscience | www.frontiersin.org 12 August 2020 | Volume 14 | Article 879
